Capecitabine Medac الاتحاد الأوروبي - الإنجليزية - EMA (European Medicines Agency)

capecitabine medac

medac gesellschaft für klinische spezialpräparate mbh - capecitabine - colorectal neoplasms - antineoplastic agents - capecitabine medac is indicated for the adjuvant treatment of patients following surgery of stage-iii (dukes’ stage-c) colon cancer.capecitabine medac is indicated for the treatment of metastatic colorectal cancer.capecitabine medac is indicated for first-line treatment of advanced gastric cancer in combination with a platinum-based regimen.capecitabine medac in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. previous therapy should have included an anthracycline.capecitabine medac is also indicated as monotherapy for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline-containing chemotherapy regimen or for whom further anthracycline therapy is not indicated.

Capecitabine Teva الاتحاد الأوروبي - الإنجليزية - EMA (European Medicines Agency)

capecitabine teva

teva pharma b.v. - capecitabine - colonic neoplasms; breast neoplasms; colorectal neoplasms; stomach neoplasms - antineoplastic agents - capecitabine teva is indicated for the adjuvant treatment of patients following surgery of stage iii (dukes’ stage c) colon cancer.capecitabine teva is indicated for the treatment of metastatic colorectal cancer.capecitabine teva is indicated for first‑line treatment of advanced gastric cancer in combination with a platinum‑based regimen.capecitabine teva in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. previous therapy should have included an anthracycline. capecitabine teva is also indicated as monotherapy for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline containing chemotherapy regimen or for whom further anthracycline therapy is not indicated.

TARO-CAPECITABINE TABLET كندا - الإنجليزية - Health Canada

taro-capecitabine tablet

taro pharmaceuticals inc - capecitabine - tablet - 150mg - capecitabine 150mg - antineoplastic agents

TARO-CAPECITABINE TABLET كندا - الإنجليزية - Health Canada

taro-capecitabine tablet

taro pharmaceuticals inc - capecitabine - tablet - 500mg - capecitabine 500mg - antineoplastic agents

APO-Capecitabine نيوزيلاندا - الإنجليزية - Medsafe (Medicines Safety Authority)

apo-capecitabine

apotex nz ltd - capecitabine 150mg - film coated tablet - 150 mg - active: capecitabine 150mg excipient: colloidal silicon dioxide croscarmellose sodium hyprolose hypromellose iron oxide red iron oxide yellow lactose macrogol 8000 magnesium stearate methylcellulose titanium dioxide - breast cancer capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline containing chemotherapy regimen unless therapy with these and other standard agents are clinically contraindicated. capecitabine in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy. colon cancer capecitabine is indicated for the adjuvant treatment of patients with dukes' stage c and high risk stage b colon cancer, either as monotherapy or in combination with oxaliplatin. colorectal cancer capecitabine is indicated for first-line treatment of patients with metastatic colorectal cancer. oesophagogastric cancer capecitabine is indicated for the first line treatment of patients with advanced oesophagogastric cancer in combination with a platinum-based regimen.

APO-Capecitabine نيوزيلاندا - الإنجليزية - Medsafe (Medicines Safety Authority)

apo-capecitabine

apotex nz ltd - capecitabine 500mg - film coated tablet - 500 mg - active: capecitabine 500mg excipient: colloidal silicon dioxide croscarmellose sodium hyprolose hypromellose iron oxide red iron oxide yellow lactose macrogol 8000 magnesium stearate methylcellulose titanium dioxide - breast cancer capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline containing chemotherapy regimen unless therapy with these and other standard agents are clinically contraindicated. capecitabine in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy. colon cancer capecitabine is indicated for the adjuvant treatment of patients with dukes' stage c and high risk stage b colon cancer, either as monotherapy or in combination with oxaliplatin. colorectal cancer capecitabine is indicated for first-line treatment of patients with metastatic colorectal cancer. oesophagogastric cancer capecitabine is indicated for the first line treatment of patients with advanced oesophagogastric cancer in combination with a platinum-based regimen.

TEVA-CAPECITABINE TABLET كندا - الإنجليزية - Health Canada

teva-capecitabine tablet

teva canada limited - capecitabine - tablet - 150mg - capecitabine 150mg - antineoplastic agents

TEVA-CAPECITABINE TABLET كندا - الإنجليزية - Health Canada

teva-capecitabine tablet

teva canada limited - capecitabine - tablet - 500mg - capecitabine 500mg - antineoplastic agents

ACH-CAPECITABINE TABLET كندا - الإنجليزية - Health Canada

ach-capecitabine tablet

accord healthcare inc - capecitabine - tablet - 150mg - capecitabine 150mg - antineoplastic agents

ACH-CAPECITABINE TABLET كندا - الإنجليزية - Health Canada

ach-capecitabine tablet

accord healthcare inc - capecitabine - tablet - 500mg - capecitabine 500mg - antineoplastic agents